The Rheumatology Advanced Practice Providers (RhAPP)

Welcome to the Content Rheum! RhAPP is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

bshape_img

bgdots

bshape_img

section_img

Faculty

Candace Ryan

PA-C

Arizona Arthritis and Rheumatology Associates

Jeannette Hart

PA-C

Kadlec Clinic Rheumatology

Stacey Johnson

FNP-C

Montana Arthritis Center

Audrey Gibson

PA-C

Arthritis Center of North Georgia

Cassie Dolecki

PharmD

Autoimmunity Institute, Allegheny Health Network

Jennifer Mylod

DNP

Arizona Arthritis and Rheumatology Associates

William Saalfeld

NP

Arthritis Center of Nebraska

Wendy Simmons

PA-C

Carolina Arthritis Associates

Claudia Rivera Salas

NP

Lansing Rheumatology

Ingrid Pan

PharmD, BCPPS

University of Colorado

Christy Vath

PA-C

Seattle Rheumatology Associates Seattle, Washington

Jessica Farrell

PharmD

Albany Medical Center Division of Rheumatology Albany, New York

Heather Mambretti

PA-C

Texas Rheumatology

Robert Laugherty

JD, MBA, PA-C

East Tennessee Medical Group

Kyle George

PA-C

Boise, ID

Amanda Mixon

PA-C

UCHealth

Amber Hudgins

PharmD, SCP, CPP

Novant Health

Danielle Gatti-Palumbo

PharmD

Northwell Health Division of Rheumatology

Katie Springer

PA-C

Northwestern Medicine Lake Forest Hospital

Podcasts

RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines

The Clinical Utility of Guselkumab in Axial PsA

RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk

Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control

Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights

CD64+ Binding Description, Relevance, and Potential Clinical Implications

Biosimilars and The Patient Perspective

RhAPPcast: Biosimilars Unveiled - Empowering APPs for Better Patient Conversations

RhAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD

IL-23

How Does Real-World Evidence Differ From Randomized Controlled Trials?

How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?

What Is the Safety Profile of Guselkumab in PsO and PsA?

How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically?

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Why is Binding CD64+ Important When Discussing IL23 Directed Therapy?

How Is Guselkumab Dosed in PsO, PsA, and IBD?

Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

What is The Role of IL23/IL17 Axis in Rheumatic Disease

Describe the IL23/IL17 Axis

Describe The Mechanism of Action of Guselkumab

Define, Compare, and Contrast Humoral and Cell-Mediated Immunity

What is Non-Responder Imputation and How is it Utilized in Clinical Trials

Data Review From the Phase III DISCOVER-2 Trials

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

IL-17

Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)

What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?

What Is the Safety Profile of Ixekizumab in PsA and axSpa?

Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA

Describe The Mechanism of Action of Ixekizumab

Describe the IL17-Induced Inflammatory Cascade

JAK

Safety and Efficacy of Upadacitinib for Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase-1 Trial

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies

What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?

What Is the Safety Profile of Upadacitinib Across Indications?

Variability in JAK Inhibition Specificity & Its Clinical Implications

How Is Upadacitinib Dosed Across Rheumatologic Indications?

Describe the Mechanism of Action of Upadacitinib

Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease

Describe JAK-STAT signaling in inflammation

Biosimilars

What Is the Difference Between Biosimilars and Generics?

What Does It Mean for a Biosimilar to Be Interchangeable and Why Is That Important?

csDMARDS

Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs

Lupus Nephritis

How is Lupus Nephritis Defined?

How Long Has It Been Since the Last ACR LN Guideline Updates and Why Is This Significant?

section_img

dot_img

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play